10/8/2020 8:09:19 AM
Corbus Plans Restructuring That Will Result In Reduction Of Workforce By 54%
10/6/2020 7:09:13 AM
Corbus Pharma Says Phase 2b Study Of Lenabasum Fails To Meet Primary Endpoint
9/8/2020 7:15:26 AM
Corbus Pharma Says RESOLVE-1 Trial Did Not Meet Its Primary Endpoint
7/8/2020 8:14:51 AM
Corbus Pharma Appoints George Golumbeski To Board
7/8/2020 8:07:36 AM
Corbus Pharmaceuticals Appoints George Golumbeski To Board
6/22/2020 8:27:51 AM
Corbus Says Last Subject Completed Final Visit In Phase 2b JBT101-CF-002 Trial
6/1/2020 8:17:06 AM
Corbus Reports Baseline Patient Demographics & Disease Characteristics In Phase 2b Study Of Lenabasum In Cystic Fibrosis
5/27/2020 8:16:17 AM
Corbus Pharma Reports Last Subject Visit In RESOLVE-1 Phase 3 Study Of Lenabasum For Systemic Sclerosis